Eli Lilly says its Foundayo pill reduces sleep apnea severity
Eli Lilly said its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity in a late-stage trial. The drugmaker plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe sleep apnea in adults with obesity or who are overweight. Foundayo has been available in the U.S. since April and joins other GLP-1 treatments showing results in the condition.
In 40 seconds
- Foundayo cut the apnea-hypopnea index by 21.1 events per hour in patients not using PAP therapy, versus 4.8 with placebo, at 52 weeks.
- Among PAP users, the reduction was 18.3 events per hour versus 5.5 for placebo.
- Lilly plans to submit the results to the FDA by the end of the year for moderate-to-severe obstructive sleep apnea.
Read the full story at CNBC
IASummary generated by artificial intelligence from a story by CNBC. It may contain errors: the original source prevails.
Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.